Skip to main content
S&P 5007,541.40-0.51%DOW51,983.98+0.41%NASDAQ25,164.36-1.07%BTC$77,142.00-1.60%ETH$2,258.53-1.35%GOLD$3,958.40-0.28%OIL$96.61+0.16%
Smart Investors Daily
SID Premium
IF

NASDAQ · IFRX

InflaRx N.V.

Healthcare · Biotechnology

$1.77

Up+$0.11 (+6.33%)

Updated Nov 3, 2026, 3:20 AM

SID Score

4.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
69.1M
P/E ratio
-1.3
Dividend yield
0.00%
52-week range
$0.80 – $2.95
Volume
800.52K
Avg. volume
2.87M

Price performance · IFRX

IFRX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

IFRX closed at $1.77 after 21 trading sessions, up 5.06% for the selected period.

Last close
$1.77
Period change
+5.06%
Period low
$1.32
Period high
$1.77
Daily close
View OHLC price history
IFRX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$1.68$1.79$1.63$1.765800.52K
Oct 30, 2026$1.71$1.72$1.6208$1.66691.45K
Oct 29, 2026$1.74$1.79$1.71$1.715306.54K
Oct 28, 2026$1.67$1.74$1.65$1.73493.94K
Oct 27, 2026$1.59$1.66$1.57$1.66513.06K
Oct 26, 2026$1.56$1.615$1.54$1.575397.59K
Oct 23, 2026$1.51$1.585$1.48$1.56889.58K
Oct 22, 2026$1.55$1.60$1.51$1.53404.21K
Oct 21, 2026$1.55$1.61$1.54$1.55701.42K
Oct 20, 2026$1.45$1.61$1.44$1.54724.08K
Oct 19, 2026$1.33$1.48$1.285$1.452.81M
Oct 16, 2026$1.47$1.475$1.29$1.321.54M
Oct 15, 2026$1.47$1.53$1.43$1.44552.04K
Oct 14, 2026$1.53$1.5364$1.46$1.48585.67K
Oct 13, 2026$1.59$1.605$1.54$1.55367.91K
Oct 12, 2026$1.60$1.64$1.545$1.59467.93K
Oct 9, 2026$1.55$1.695$1.546$1.60740.71K
Oct 8, 2026$1.55$1.60$1.47$1.531.14M
Oct 7, 2026$1.60$1.60$1.55$1.56460.35K
Oct 6, 2026$1.69$1.78$1.565$1.58720.67K
Oct 5, 2026$1.70$1.72$1.65$1.68701.01K

Latest IFRX news

The latest Smart Investors Daily articles mentioning IFRX.

Stock researchCompany · Overview

IFRX research

Overview

Company profile and research snapshot.

Company profile

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$2.00
Implied upside
—
Analysts
—
IFRX recent ratings
DateFirmRatingTarget
Sep 14, 2026NeedhamBuy—
Aug 7, 2026Cantor FitzgeraldOverweight—
May 13, 2026Raymond JamesStrong Buy—
May 11, 2026HC Wainwright & Co.Buy—
May 11, 2026Cantor FitzgeraldOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 27, 2026

InflaRx Announces November Investor Events

Jena, Germany, Oct. 27, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its events calendar for November. Guggenheim Securities 3rd Annual Healthcare Innovation ConferenceNovember 9 – 11, 2026 in Boston, MAFireside chat on November 10 at 9:30 AM ESTInflaRx will also conduct one-on-one investor meetings on November 10th. A link to view the fireside chat live stream and i

Yahoo · Oct 22, 2026

InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026

Data from pre-clinical renal disease models demonstrate potential of izicopan for kidney protectionStructural modeling provides new insight into izicopan’s differentiated molecular profile Jena, Germany, Oct. 22, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the presentation of new pre-clinical data on izicopan in renal disease models at the American Society of Nephro

Yahoo · Oct 2, 2026

InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026

Jena, Germany, Oct. 02, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company has been selected for a late-breaking poster session at the American Society of Nephrology’s Kidney Week 2026, taking place in Denver, Colorado, USA, October 21 - 25. Kidney Week 2026 Late-Breaking Poster Details Title: Izicopan, a Second-Generation Oral C5a Receptor 1 (C5aR1) Antag

Yahoo · Oct 1, 2026

InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development

Jena, Germany, Oct. 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development, effective October 1, 2026. Dr. Alperovich is a physician-scientist and nephrologist with more than two decades of experience in the global pharmaceutical industry, spanning senior leaders

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By